Abbott and AstraZeneca announced today a collaboration to co-develop and market a combination treatment that will target all three important blood lipids — LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and triglycerides — in one single pill as part of a comprehensive treatment regimen. Under the agreement, the companies will initiate two parallel programs: a CRESTOR (rosuvastatin calcium)/TriCor (fenofibrate tablets) fixed-dose combination and a CRESTOR/ABT-335 combination. ABT-335 is Abbott's proprietary next-generation fenofibrate currently in Phase III clinical trials.
PR Newswire
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Biom’up’s Laparoscopic Applicator Earns New Marketing Approval
The device quickly delivers Hemoblast powder to bleeding areas in minimally-invasive surgeries.
Lawmakers Want Probe of BMS/Celgene Deal
The cancer drugs the company will acquire as part of the deal include Celgene’s blockbuster drug Revlimid.
FDAnews Drug Daily Bulletin
ABBOTT AND ASTRAZENECA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE CRESTOR AND NEXT-GENERATION TRICOR FIXED-DOSE COMBINATION
July 6, 2006
